Summary & Overview
CPT 0321U: Urinary Tract Infection Detection and Resistance Test
CPT code 0321U designates a proprietary laboratory molecular assay — the Bridge Urinary Tract Infection Detection and Resistance Test from Bridge Diagnostics — that identifies up to 20 specific bacterial or fungal organisms in urine and screens for 16 antibiotic resistance genes. The code matters nationally as molecular diagnostics for urinary tract infections (UTIs) can change diagnostic workflows, influence antibiotic stewardship, and affect reimbursement and coverage policies as labs adopt proprietary panels.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical service setting, and which payers are addressed. The publication summarizes common billing modifiers and situates the code within laboratory service lines. It also outlines what to expect in policy and coverage reviews for PLA codes, how this test fits into antibiotic-resistance detection efforts, and practical considerations for documentation and claims submission.
This national-oriented summary provides clinicians, laboratory administrators, and billing professionals with the clinical context and payer focus needed to assess adoption implications and prepare for payer-specific policy inquiries and claims processing.
Billing Code Overview
CPT code 0321U is a Proprietary Laboratory Analyses (PLA) code for the Bridge Urinary Tract Infection Detection and Resistance Test from Bridge Diagnostics. The test uses multiple nucleic acid probes to detect any of 20 specific bacterial or fungal organisms in a urine specimen and includes probes for 16 associated antibiotic resistance genes. Results may help clinicians identify the likely causative organism for a urinary tract infection and inform selection of antibiotic therapy or indicate need for further testing.
Service type: Proprietary laboratory molecular diagnostic test (nucleic acid probe panel)
Typical site of service: Clinical laboratory or outpatient laboratory facility
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult woman presenting to an urgent care clinic or primary care office with symptoms suggestive of a urinary tract infection (UTI) such as dysuria, urinary frequency, urgency, suprapubic pain, or hematuria. The clinician collects a clean-catch midstream urine specimen and orders the Bridge Urinary Tract Infection Detection and Resistance Test (0321U) to rapidly identify bacterial or fungal pathogens and associated resistance genes when empiric therapy is uncertain, the patient has recurrent infections, recent antibiotic exposure, complicated urinary anatomy, or risk factors for resistant organisms. The specimen is sent to the performing laboratory; the lab uses multiple nucleic acid probes to detect up to 20 specific organisms and 16 resistance genes. Results are returned to the clinician, who uses organism identification and resistance marker information to refine antibiotic selection, guide the need for urine culture or additional testing, or determine specialist referral. Typical sites of service include outpatient clinics, urgent care centers, emergency departments, and independent clinical laboratories. The service type is laboratory molecular diagnostic testing (Proprietary Laboratory Analyses).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no specific modifier applies to the billed service. |